ASX ANNOUNCEMENT **29 JUNE 2022**

CHIMERIC LICENSES VIRAL VECTOR TECHNOLOGY FROM UNIVERSITY OF PENNSYLVANIA FOR CDH17 CAR T PROGRAM

Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) therapies.

Under the amended agreement, Chimeric has acquired a non-exclusive know-how license to use Penn's third-generation lentiviral vector plasmid system for the development and commercialization of CHM 2101 (CDH17 CAR T). Viral vector is a critical component used in the manufacturing of CAR T cells, and third-generation lentiviral vectors offer improved safety over earlier generations[1].

The amended license will enable Chimeric to manufacture clinical-grade lentiviral vector for use in its planned phase 1 study of CHM 2101 (CDH17 CAR T) for gastrointestinal cancers.

In addition, Chimeric is able to cross-reference regulatory information on file with the US FDA to facilitate filing of an Investigational New Drug (IND) for CHM 2101.

Under the original license agreement in July 2021, Chimeric acquired the exclusive rights to develop and commercialize certain CDH17 CAR T cell therapies licensed from Penn.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

1. Milone, M.C., O'Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529–1541 (2018).

ABOUT THE AGREEMENT

Whilst the cost to Chimeric of the license amendment is not considered financially material in the context of Chimeric's annual budgeted expenditure, the nature of the agreement is considered market sensitive. The upfront licensing fee is expected to be funded from existing cash reserves. There are no conditions precedent and the license amendment is effective immediately.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in metastatic melanoma with future expansion to additional solid tumours.

CHM 2101 (CDH17 CAR T) is based on a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au